Answers are grounded in this paper and cite their sources.
Integrative analysis highlights ANXA1 and ARG2's roles in T cell proliferation during ischemia-reperfusion injury, suggesting therapeutic targets.
Ischemia-reperfusion injury (IRI) represents a common pathophysiological condition and serves as a shared mechanism underlying diverse critical diseases, including acute kidney injury, myocardial infarction, and stroke. T cells are increasingly recognized as central mediators of immune responses during IRI; however, the mechanisms governing their proliferation remain poorly characterized. Herein, an integrative analysis of bulk and single-cell transcriptomic datasets across multiple organ models was performed to investigate the role of T cell proliferation–related genes in IRI. We identified ANXA1 and ARG2 as key IRI-associated genes, both of which exhibited consistent upregulation during the early stages of injury. Immune infiltration analysis demonstrated that ANXA1 expression correlated most strongly with central memory CD4 + T cell infiltration, whereas ARG2 was linked to T helper 17 cell infiltration. Drug prediction and molecular dynamics simulation further identified Hydrocortamate and NS6180 as potential therapeutic agents targeting T cell proliferation. Single-cell RNA sequencing not only confirmed the active involvement of T cells in IRI progression but also highlighted ANXA1 as a particularly prominent regulator. A renal IRI model was also used to further confirm altered T cell activity and differential expression of these key genes in vivo . Collectively, these findings elucidate the molecular mechanisms driving T cell proliferation in IRI, positioning ANXA1 and ARG2 as promising pan-organ IRI biomarkers and therapeutic targets for mitigating tissue damage and promoting repair.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: